IXHL Logo

Incannex Healthcare Limited (IXHL) Stock Forecast & Price Prediction

Live IXHL Stock Price & Analysis

Home โ€บ Stocks โ€บ Australia | NASDAQ | Healthcare | Drug Manufacturers - Specialty & Generic

$2.10

-0.10 (-4.55%)

12 Month Price Forecast For IXHL

$2.10
Current Price
$38.81M
Market Cap
0 Ratings
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to IXHL Price Forecasts

N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A

IXHL Price Momentum

+25.7%
1 Week Change
+14.8%
1 Month Change
-30.9%
1 Year Change
-0.9%
Year-to-Date Change
-75.2%
From 52W High of $8.47
+40.0%
From 52W Low of $1.50

๐Ÿค” Considering Incannex (IXHL)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 8, 2025 3:50 AM UTC

IXHL Analyst Ratings & Price Targets

Currently, there are no Wall Street analyst price targets or forecasts available for IXHL (Incannex).

IXHL is currently trading at $2.10. Without active analyst coverage, investors should conduct thorough independent research and consider multiple data points beyond price targets when evaluating this stock for their portfolio.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

IXHL Analyst Consensus

0
Buy
0
Hold
0
Sell

IXHL Price Target Range

Low
N/A
Average
N/A
High
N/A
Current: $2.10

Latest IXHL Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for IXHL.

Date Firm Analyst Rating Change Price Target
Dec 8, 2022 Mizuho Neutral Maintains $0.00
Nov 16, 2022 Keybanc Sector Weight Downgrade $0.00
Nov 3, 2022 Mizuho Neutral Downgrade $0.00
Nov 3, 2022 Truist Securities Hold Downgrade $0.00
Nov 3, 2022 Raymond James Outperform Maintains $0.00
Nov 3, 2022 RBC Capital Outperform Maintains $0.00
Nov 3, 2022 Barclays Overweight Maintains $0.00
Oct 24, 2022 Morgan Stanley Equal-Weight Maintains $0.00
Oct 24, 2022 Truist Securities Buy Maintains $0.00
Oct 24, 2022 Keybanc Overweight Maintains $0.00
Oct 24, 2022 RBC Capital Outperform Maintains $0.00
Oct 21, 2022 Needham Hold Downgrade $0.00
Oct 17, 2022 Mizuho Buy Maintains $0.00
Oct 11, 2022 Canaccord Genuity Buy Initiates $0.00
Sep 23, 2022 BTIG Neutral Initiates $0.00
Aug 4, 2022 Mizuho Buy Maintains $0.00
Aug 4, 2022 Morgan Stanley Equal-Weight Maintains $0.00
Aug 4, 2022 Raymond James Outperform Maintains $0.00
Aug 4, 2022 Needham Buy Maintains $0.00
Aug 1, 2022 RBC Capital Outperform Maintains $0.00

Stocks Similar to Incannex Healthcare Limited

The following stocks are similar to Incannex based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Incannex Healthcare Limited (IXHL) Financial Data

Incannex Healthcare Limited has a market capitalization of $38.81M with a P/E ratio of -1.9x. The company generates $12,000 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is +516.7% quarter-over-quarter, while maintaining an operating margin of -53,833.3% and return on equity of -115.2%.

Valuation Metrics

Market Cap $38.81M
Enterprise Value $29.80M
P/E Ratio -1.9x
PEG Ratio -1.1x
Price/Sales 3,234.5x

Growth & Margins

Revenue Growth (YoY) +516.7%
Gross Margin N/A
Operating Margin -53,833.3%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +15.8%
Current Ratio 2.9x
Debt/Equity 3.3x
ROE -115.2%
ROA -57.0%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Incannex Healthcare Limited logo

Incannex Healthcare Limited (IXHL) Company Overview

About Incannex Healthcare Limited

What They Do

Develops psychedelic medicines for chronic diseases.

Business Model

The company operates as a clinical-stage biopharmaceutical firm, focusing on the research, development, manufacture, sale, and distribution of innovative psychedelic therapies. It generates revenue through clinical trials and potential commercialization of its drug candidates, including IHL-42X and PSX-001, targeting various chronic conditions.

Additional Information

Incannex Healthcare is headquartered in Sydney, Australia, and is actively pursuing multiple clinical trials to expand its portfolio of treatments for diseases such as obstructive sleep apnea, generalized anxiety disorder, rheumatoid arthritis, and other inflammatory conditions.

Company Information

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

9

CEO

Mr. Joel Bradley Latham

Country

Australia

IPO Year

2022

Incannex Healthcare Limited (IXHL) Latest News & Analysis

IXHL stock latest news image
Quick Summary

Dr. Wimms has joined the team, bringing significant experience in industry and clinical development focused on sleep medicine innovation.

Why It Matters

Dr. Wimms' expertise in sleep medicine could indicate potential advancements or new products, impacting company performance and stock value in the healthcare sector.

Source: GlobeNewsWire
Market Sentiment: Neutral
IXHL stock latest news image
Quick Summary

Incannex Healthcare Inc. (Nasdaq: IXHL) reported positive topline results from a pharmacokinetics and safety study of IHL-42X, a novel treatment for Obstructive Sleep Apnea.

Why It Matters

Positive results from Incannex's IHL-42X study could boost investor confidence, indicating potential for market approval and revenue growth in a lucrative therapeutic area.

Source: GlobeNewsWire
Market Sentiment: Neutral
IXHL stock latest news image
Quick Summary

Incannex Healthcare Inc. (NASDAQ: IXHL) reported 1Q 2025 R&D costs of $2.9M, a $0.3M increase from 1Q 2024, according to Stonegate Capital Partners' updated coverage.

Why It Matters

Increased R&D costs may indicate a focus on innovation, potentially impacting future growth and profitability for Incannex Healthcare Inc. Shareholder sentiment could be affected.

Source: Newsfile Corp
Market Sentiment: Neutral
IXHL stock latest news image
Quick Summary

Incannex Healthcare Inc. (Nasdaq: IXHL) reported its fiscal Q1 results for the quarter ending September 30, 2024, highlighting its focus on innovative medicines for chronic diseases.

Why It Matters

Incannex's fiscal first quarter results can indicate its financial health and progress in drug development, affecting investor sentiment and potential stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
IXHL stock latest news image
Quick Summary

Incannex Healthcare Inc. appointed Dr. Lou Barbato as Chief Medical Officer. He has extensive drug development experience and will support the company's clinical programs in several chronic diseases.

Why It Matters

The appointment of an experienced CMO signals potential advancement in drug development, which could enhance Incannex's clinical programs and attract investor confidence.

Source: GlobeNewsWire
Market Sentiment: Neutral
IXHL stock latest news image
Quick Summary

Stonegate Capital Partners initiates coverage on Incannex Healthcare Inc. (NASDAQ: IXHL), which is advancing cannabinoid and psychedelic therapeutics and conducting an FDA trial for Obstructive Sleep Apnea. Top-line data expected in H1 2025.

Why It Matters

Stonegate Capital Partners' coverage initiation on Incannex Healthcare highlights potential growth from its innovative cannabinoid therapies and upcoming clinical trial results, impacting investor sentiment.

Source: Newsfile Corp
Market Sentiment: Neutral

Frequently Asked Questions About IXHL Stock

What is Incannex Healthcare Limited's (IXHL) stock forecast for 2025?

Analyst forecasts for Incannex Healthcare Limited (IXHL) are not currently available. The stock is trading at $2.10.

Is IXHL stock a good investment in 2025?

Analyst ratings for IXHL are not currently available. The stock is currently trading at $2.10. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for IXHL stock?

Price predictions from Wall Street analysts for IXHL are not currently available. The stock is trading at $2.10.

What is Incannex Healthcare Limited's business model?

The company operates as a clinical-stage biopharmaceutical firm, focusing on the research, development, manufacture, sale, and distribution of innovative psychedelic therapies. It generates revenue through clinical trials and potential commercialization of its drug candidates, including IHL-42X and PSX-001, targeting various chronic conditions.

What is the highest forecasted price for IXHL Incannex Healthcare Limited?

Price targets from Wall Street analysts for IXHL are not currently available. The stock is trading at $2.10.

What is the lowest forecasted price for IXHL Incannex Healthcare Limited?

Price targets from Wall Street analysts for IXHL are not currently available. The stock is trading at $2.10.

What is the overall IXHL consensus from analysts for Incannex Healthcare Limited?

Analyst ratings for IXHL are not currently available. The stock is trading at $2.10.

How accurate are IXHL stock price projections?

Stock price projections, including those for Incannex Healthcare Limited, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.